Trial Profile
A Randomized,Double-Blind, Placebo-Controlled, Multicenter, Phase II Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Famitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms HR-FMTN-NSCLC-MON
- Sponsors Jiangsu Hengrui Medicine Co.
- 31 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 31 Oct 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 31 Oct 2019 Status changed from active, no longer recruiting to suspended.